Literature DB >> 21509733

[Balance of proteinases and antiproteinases and smoking tobacco].

Joanna Kołodziejczyk1, Milena Wojciechowska, Zbigniew Bartuzi, Andrzej Dziedziczko.   

Abstract

Smoking tobacco can induce formation of inflammable state in respiratory tract and cause lungs damage. Experimental investigations affirm, that the exposure to tobacco smoke causes growth of penetrability of blood-vessels, which favors the enlarged migration of inflammable cells. The growth of exposure to reactive forms of oxygen and concentration changes of cellular antioxidants enzymes, leads to disorders in balance of proteinases and antiproteinases and oxidative stress. As the years go, the disorders mentioned above can lead to deterioration of ventilating efficiency of lungs, and consequently to pronouncement chronic obstructive pulmonary disease (COPD), which becomes serious problem on a world scale.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21509733

Source DB:  PubMed          Journal:  Pneumonol Alergol Pol        ISSN: 0867-7077


  3 in total

1.  Emphysema: A Potential Risk Factor for Subarachnoid Hemorrhage and Ruptured Aortic Aneurysm

Authors:  Ali Mahta; Alexander E Merkler; Michael E Reznik; Jaclyn E Burch; Shadi Yaghi; Frank W Sellke; Karen L Furie; Hooman Kamel
Journal:  Stroke       Date:  2019-04       Impact factor: 7.914

2.  Activity of α1-antitrypsin and some lysosomal enzymes in the blood serum of patients with chronic obstructive pulmonary disease after smoking cessation.

Authors:  Bartosz Woźniak; Alina Woźniak; Jacek Konca; Dariusz Górecki; Celestyna Mila-Kierzenkowska; Michał Szpinda; Paweł Sutkowy; Roland Wesołowski
Journal:  Biomed Res Int       Date:  2015-01-31       Impact factor: 3.411

3.  Knockdown of Alpha-1 Antitrypsin with antisense oligonucleotide does not exacerbate smoke induced lung injury.

Authors:  Kyle Stearns; Monica Goldklang; Rui Xiao; Tina Zelonina; Keith Blomenkamp; Jeffery Teckman; Jeanine M D'Armiento
Journal:  PLoS One       Date:  2021-02-04       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.